Maternal drug adverse effects (6 hours after administration) · women with perineal pain in the early postpartum period
It is very uncertain whether NSAID (single administration, any dose) changes maternal drug adverse effects (6 hours after administration) compared with paracetamol (very low certainty).
1 finding from 1 review
Neonatal drug adverse effects ‐ not reported · women with perineal pain in the early postpartum period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for additional analgesia (4 hours after administration) · women with perineal pain in the early postpartum period
NSAID probably leads to lower need for additional analgesia(4 hours after administration) compared with placebo (moderate certainty).
1 finding from 1 review
Need for additional analgesia (6 hours after administration) · women with perineal pain in the early postpartum period
It is very uncertain whether NSAID changes need for additional analgesia (6 hours after administration) compared with placebo (very low certainty).
1 finding from 1 review
Maternal drug adverse effects(4 hours after administration) · women with perineal pain in the early postpartum period
1 finding from 1 review
Maternal drug adverse effects (6 hours after administration) · women with perineal pain in the early postpartum period
NSAID showed no clear difference in maternal drug adverse effects(6 hours after administration) compared with placebo (low certainty).
1 finding from 1 review
Neonatal drug adverse effects · women with perineal pain in the early postpartum period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of pain · women with perineal pain in the early postpartum period
NSAID (single administration, any dose) may leads to higher adequate pain relief (4 hours after administration) compared with paracetamol (low certainty).
2 findings from 1 review
Hypertensive disorders of pregnancy · women with gestational diabetes mellitus
Metformin showed no clear difference in hypertensive disorders of pregnancy compared with glibenclamide ‐ maternal outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women with gestational diabetes mellitus
Metformin showed no clear difference in caesarean section compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Development of type 2 diabetes ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Perineal trauma · women with gestational diabetes mellitus
Metformin showed no clear difference in perineal trauma compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Return to pre‐pregnancy weight ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postnatal depression ‐ not measured · women with gestational diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of labour · women with gestational diabetes mellitus
Metformin showed no clear difference in induction of labour compared with glibenclamide ‐ maternal outcomes (low certainty).
1 finding from 1 review
Large‐for‐gestational age · Infants of women diagnosed with gestational diabetes
Metformin showed no clear difference in large‐for‐gestational age compared with glibenclamide ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Perinatal mortality · Infants of women diagnosed with gestational diabetes
It is very uncertain whether metformin changes perinatal mortality compared with glibenclamide ‐ neonatal outcomes (very low certainty).
1 finding from 1 review
Death or serious morbidity composite · Infants of women diagnosed with gestational diabetes
Metformin may leads to lower death or serious morbidity composite compared with glibenclamide ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Neonatal hypoglycaemia · Infants of women diagnosed with gestational diabetes
Metformin showed no clear difference in neonatal hypoglycaemia compared with glibenclamide ‐ neonatal outcomes (low certainty).
1 finding from 1 review
Adiposity ‐ not reported · Infants of women diagnosed with gestational diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found